Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ENROLLING_BY_INVITATION
NA
335 participants
INTERVENTIONAL
2023-07-28
2027-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Smart Lighting for Nursing Home Residents With Dementia
NCT05825404
Impact of an Automatic Alert Device on the Occurrence of Nocturnal Falls in Nursing Home Residents
NCT05964972
Determining How Indoor Lighting Affects the Brain Health of Older Adults
NCT05978934
Preliminary Clinical Trial- FallScape-D
NCT06656897
Lighting for Older Adults With Dementia
NCT05697757
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A significant number of these falls occur in the bedroom during the evening and night, when AL staff are not present, thereby limiting their ability to intervene. However, the cause of many of these falls -- impaired nighttime vision and related postural instability -- suggests a promising avenue for intervention.
This project will test the effectiveness of a novel intervention consisting of unobtrusive, low-intensity, horizontal and vertical lights that outline the bathroom or entry way doorframe in residents' rooms and provide visual cues to promote postural stability. The lighting system is particularly attractive and pragmatic because it is low cost, requires no staff involvement, and can be easily installed in new buildings or retrofitted to existing buildings.
The study investigators recently completed a NIH R21 exploratory/developmental randomized crossover trial of this system and found a 34% decrease in falls due to a novel lighting intervention. This NIH R01 project will build on that preliminary effort; if the results are as promising as suggested, this pragmatic passive lighting system has the potential to reduce falls and related sequelae for countless persons with Alzheimer's disease and related dementias, and to become a new standard of care.
The intervention being tested is the effectiveness of a novel intervention consisting of unobtrusive, low-intensity, horizontal and vertical lights that outline the bathroom or entry way doorframe in assisted living (AL) residents' rooms in preventing night time falls. The trial will enroll 335 AL residents with Alzheimer's disease and related dementias (ADRD) from 36 assisted living communities. The lighting will be installed in the rooms of all 335 enrolled AL residents and compared to standard nightlights (control condition). Using a randomized crossover trial design, subjects will be examined under both conditions over one year. The trial will enroll 36 communities over the course of three years. Falls will be measured using SafelyYou, a fall detection system that uses video cameras and artificial intelligence to detect falls in resident rooms while maintaining resident privacy."
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
HEALTH_SERVICES_RESEARCH
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Lighting Sequence 1: CCLL
In this arm, the participant will receive the control lighting condition (C) for the first two quarters (180 days) and then crossover to the novel lighting condition (L) for the last two quarters (180 days).
Q1 - Control lighting Q2 - Control lighting Q3 - Novel lighting Q4 - Novel lighting
Novel Lighting Condition
Horizontal and vertical lights over a doorway visible from the bed
Control Lighting Condition
Standard night light plugged into wall socket
Lighting Sequence 2: CLLC
In this arm, the participant will receive the control lighting condition (C) for the first quarter (90 days) and then crossover to the novel lighting condition (L) for the next two quarters (180 days) and finally crossover again to the control condition (C) for the last quarter (90 days).
Q1 - Control lighting Q2 - Novel lighting Q3 - Novel lighting Q4 - Control lighting
Novel Lighting Condition
Horizontal and vertical lights over a doorway visible from the bed
Control Lighting Condition
Standard night light plugged into wall socket
Lighting Sequence 3: LCCL
In this arm, the participant will receive the novel lighting condition (L) for the first quarter (90 days) and then crossover to the control lighting condition (C) for the next two quarters (180 days) and finally crossover again to the novel condition (L) for the last quarter (90 days).
Q1 - Novel lighting Q2 - Control lighting Q3 - Control lighting Q4 - Novel lighting
Novel Lighting Condition
Horizontal and vertical lights over a doorway visible from the bed
Control Lighting Condition
Standard night light plugged into wall socket
Lighting Sequence 4: LLCC
In this arm, the participant will receive the novel lighting condition (L) for the first two quarters (180 days) and then crossover to the control lighting condition (C) for the last two quarters (180 days).
Q1 - Novel lighting Q2 - Novel lighting Q3 - Control lighting Q4 - Control lighting
Novel Lighting Condition
Horizontal and vertical lights over a doorway visible from the bed
Control Lighting Condition
Standard night light plugged into wall socket
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Novel Lighting Condition
Horizontal and vertical lights over a doorway visible from the bed
Control Lighting Condition
Standard night light plugged into wall socket
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Lives in a participating AL community
* Not blind
* Not on hospice and in a worsening state
* Not expected to die or transfer during the next 6 months
* Reside in a private room; or reside in a shared room if
1. one resident is male and one is female and both are participating in the project, or
2. they are of any gender, as long as there is a wall divider between their bedrooms
* Do not have an overnight sitter in the room every night
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute on Aging (NIA)
NIH
University of North Carolina, Chapel Hill
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sheryl Zimmerman, PhD
Role: PRINCIPAL_INVESTIGATOR
University of North Carolina, Chapel Hill
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
22-1162
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.